Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
    1.
    发明授权
    Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid 有权
    烷氧基咪唑-1-基甲基联苯羧酸的结晶形式

    公开(公告)号:US08455530B2

    公开(公告)日:2013-06-04

    申请号:US13411319

    申请日:2012-03-02

    IPC分类号: A61K31/415 C07D233/54

    CPC分类号: C07D233/70

    摘要: The invention provides a crystalline freebase form of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.

    摘要翻译: 本发明提供了4' - {2-乙氧基-4-乙基-5 - [((S)-2-巯基-4-甲基戊酰氨基)甲基]咪唑-1-基甲基} -3'-氟联苯基 - 吡啶-2-羧酸。 本发明还提供了包含结晶化合物的药物组合物,用于制备结晶化合物的方法和中间体,以及使用结晶化合物治疗高血压疾病的方法。

    Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
    2.
    发明授权
    Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid 有权
    烷氧基咪唑-1-基甲基联苯羧酸的结晶形式

    公开(公告)号:US08153675B2

    公开(公告)日:2012-04-10

    申请号:US12944041

    申请日:2010-11-11

    IPC分类号: A61K31/415 C07D233/54

    CPC分类号: C07D233/70

    摘要: The invention provides a crystalline freebase form of 4′-{2-ethoxy-4-ethyl-5-[((S) -2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2 -carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.

    摘要翻译: 本发明提供了4' - {2-乙氧基-4-乙基-5 - [((S)-2-巯基-4-甲基戊酰氨基)甲基]咪唑-1-基甲基} -3'-氟联苯基 - 2-羧酸。 本发明还提供了包含结晶化合物的药物组合物,用于制备结晶化合物的方法和中间体,以及使用结晶化合物治疗高血压疾病的方法。

    CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID
    3.
    发明申请
    CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID 有权
    烷氧基亚氨基-1-甲基苯乙烯羧酸的结晶形式

    公开(公告)号:US20110224272A1

    公开(公告)日:2011-09-15

    申请号:US12944041

    申请日:2010-11-11

    IPC分类号: A61K31/4164 A61P13/12

    CPC分类号: C07D233/70

    摘要: The invention provides a crystalline freebase form of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.

    摘要翻译: 本发明提供了4' - {2-乙氧基-4-乙基-5 - [((S)-2-巯基-4-甲基戊酰氨基)甲基]咪唑-1-基甲基} -3'-氟联苯基 - 吡啶-2-羧酸。 本发明还提供了包含结晶化合物的药物组合物,用于制备结晶化合物的方法和中间体,以及使用结晶化合物治疗高血压疾病的方法。

    CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID
    4.
    发明申请
    CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID 有权
    烷氧基亚氨基-1-甲基苯乙烯羧酸的结晶形式

    公开(公告)号:US20120309805A1

    公开(公告)日:2012-12-06

    申请号:US13411319

    申请日:2012-03-02

    IPC分类号: A61K31/4174 A61P9/04

    CPC分类号: C07D233/70

    摘要: The invention provides a crystalline freebase form of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.

    摘要翻译: 本发明提供了4' - {2-乙氧基-4-乙基-5 - [((S)-2-巯基-4-甲基戊酰氨基)甲基]咪唑-1-基甲基} -3'-氟联苯基 - 吡啶-2-羧酸。 本发明还提供了包含结晶化合物的药物组合物,用于制备结晶化合物的方法和中间体,以及使用结晶化合物治疗高血压疾病的方法。

    Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
    5.
    发明授权
    Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid 有权
    烷氧基咪唑-1-基甲基联苯羧酸的结晶形式

    公开(公告)号:US07855221B2

    公开(公告)日:2010-12-21

    申请号:US12569058

    申请日:2009-09-29

    IPC分类号: A61K31/415 C07D233/54

    CPC分类号: C07D233/70

    摘要: The invention provides a crystalline freebase form of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.

    摘要翻译: 本发明提供了4' - {2-乙氧基-4-乙基-5 - [((S)-2-巯基-4-甲基戊酰氨基)甲基]咪唑-1-基甲基} -3'-氟联苯基 - 吡啶-2-羧酸。 本发明还提供了包含结晶化合物的药物组合物,用于制备结晶化合物的方法和中间体,以及使用结晶化合物治疗高血压疾病的方法。

    CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID
    6.
    发明申请
    CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID 有权
    烷基咪唑烷-1-基甲基苯乙烯羧酸的结晶形式

    公开(公告)号:US20100081697A1

    公开(公告)日:2010-04-01

    申请号:US12569058

    申请日:2009-09-29

    CPC分类号: C07D233/70

    摘要: The invention provides a crystalline freebase form of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.

    摘要翻译: 本发明提供了4' - {2-乙氧基-4-乙基-5 - [((S)-2-巯基-4-甲基戊酰氨基)甲基]咪唑-1-基甲基} -3'-氟联苯基 - 吡啶-2-羧酸。 本发明还提供了包含结晶化合物的药物组合物,用于制备结晶化合物的方法和中间体,以及使用结晶化合物治疗高血压疾病的方法。

    CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND
    7.
    发明申请
    CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND 有权
    喹啉酮羧酰胺化合物的结晶形式

    公开(公告)号:US20140256769A1

    公开(公告)日:2014-09-11

    申请号:US14150059

    申请日:2014-01-08

    IPC分类号: C07D451/04

    CPC分类号: A61K31/46 C07D451/04

    摘要: The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms.

    摘要翻译: 本发明提供1-异丙基-2-氧代-1,2-二氢喹啉-3-羧酸{(1S,3R,5R)-8 - [(R)-2-羟基-3-(甲磺酰基) - 甲基 - 氨基)丙基] -8-氮杂双环[3.2.1]辛-3-基}酰胺或其溶剂合物。 本发明还提供包含这种结晶盐形式的药物组合物,使用这种结晶盐形式治疗与5-HT4受体活性相关的疾病的方法,以及可用于制备此类结晶盐形式的方法。

    CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND
    9.
    发明申请
    CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND 审中-公开
    喹啉酮羧酰胺化合物的结晶形式

    公开(公告)号:US20160095849A1

    公开(公告)日:2016-04-07

    申请号:US14816237

    申请日:2015-08-03

    IPC分类号: A61K31/46

    CPC分类号: A61K31/46 C07D451/04

    摘要: The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms.

    摘要翻译: 本发明提供1-异丙基-2-氧代-1,2-二氢喹啉-3-羧酸{(1S,3R,5R)-8 - [(R)-2-羟基-3-(甲磺酰基) - 甲基 - 氨基)丙基] -8-氮杂双环[3.2.1]辛-3-基}酰胺或其溶剂合物。 本发明还提供包含这种结晶盐形式的药物组合物,使用这种结晶盐形式治疗与5-HT4受体活性相关的疾病的方法,以及可用于制备此类结晶盐形式的方法。

    Crystalline form of a quinolinone-carboxamide compound
    10.
    发明授权
    Crystalline form of a quinolinone-carboxamide compound 有权
    喹啉酮 - 甲酰胺化合物的结晶形式

    公开(公告)号:US09126994B2

    公开(公告)日:2015-09-08

    申请号:US14150059

    申请日:2014-01-08

    IPC分类号: A61K31/46 C07D451/04

    CPC分类号: A61K31/46 C07D451/04

    摘要: The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms.

    摘要翻译: 本发明提供1-异丙基-2-氧代-1,2-二氢喹啉-3-羧酸{(1S,3R,5R)-8 - [(R)-2-羟基-3-(甲磺酰基) - 甲基 - 氨基)丙基] -8-氮杂双环[3.2.1]辛-3-基}酰胺或其溶剂合物。 本发明还提供包含这种结晶盐形式的药物组合物,使用这种结晶盐形式治疗与5-HT4受体活性相关的疾病的方法,以及可用于制备此类结晶盐形式的方法。